Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.54 per share a year ago.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago.
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Swiss National Bank
Swiss National Bank boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 97,000 shares of the biopharmaceutical company’s stock after acquiring an additional 8,700 shares during the period. Swiss National Bank owned about 0.21% of Celldex Therapeutics worth $3,847,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also added to or reduced their stakes in CLDX. Teacher Retirement System of Texas increased its stake in shares of Celldex Therapeutics by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 522 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 805 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Celldex Therapeutics by 3.6% during the third quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 821 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Celldex Therapeutics by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock valued at $852,000 after acquiring an additional 954 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Celldex Therapeutics by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock worth $1,041,000 after acquiring an additional 962 shares during the last quarter. Celldex Therapeutics Trading Down 4.3 % Shares of CLDX opened at $38.21 on Monday. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $53.18. The firm has a market capitalization of $2.52 billion, a P/E ratio of -13.41 and a beta of 1.60. The firm has a 50-day moving average price of $40.41 and a 200 day moving average price of $37.93. Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.19. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year. Analyst Ratings Changes A number of research analysts have weighed in on CLDX shares. Guggenheim raised their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $66.00. View Our Latest Stock Analysis on CLDX Celldex Therapeutics Profile (Free Report) Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. See Also Five stocks we like better than Celldex Therapeutics How to Invest in the FAANG Stocks MarketBeat Week in Review – 5/13 – 5/17 Dividend Screener: How to Evaluate Dividend Stocks Before Buying Take-Two Interactive Software Offers 2nd Chance for Investors Golden Cross Stocks: Pattern, Examples and Charts Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
